Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 20/20 | 0.87 |
| ▸ | PIM3 | Q86V86 | 20/20 | 0.87 |
| ▸ | PIM2 | Q9P1W9 | 20/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16588206 | 0.93 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL16754131 | 0.93 | PIM1 (0.88) | PIM1PIM3PIM2 | |
| SCHEMBL16579541 | 0.93 | PIM1 (0.88) | PIM1PIM3PIM2 | |
| SCHEMBL16579681 | 0.93 | PIM1 (0.89) | PIM1PIM3PIM2 | |
| SCHEMBL16579721 | 0.91 | PIM2 (0.87) | PIM1PIM3PIM2 | |
| SCHEMBL16579593 | 0.91 | PIM1 (0.88) | PIM1PIM3PIM2 | |
| SCHEMBL16754141 | 0.91 | PIM1 (0.88) | PIM1PIM3PIM2 | |
| SCHEMBL16579581 | 0.90 | PIM1 (0.87) | PIM1PIM3PIM2 | |
| SCHEMBL12078216 | 0.90 | PIM1 (0.88) | PIM1PIM3PIM2 | |
| SCHEMBL12078458 | 0.90 | PIM1 (0.88) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173883-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | claimed |
| US-20150133473-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-14 | — | — | US | claimed |
| US-8987457-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-03-24 | — | — | US | claimed |
| US-9173883-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150133473-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133473-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | PIM1, PIM2, MAP3K1 | PIM1 1/4885PIM3 4/4885PIM2 2/4885 |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | PIM1, PIM2, MAP3K1 | PIM1 1/4885PIM3 4/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.